Lowest-Rated StocksLowest-RatedNASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free DOCS Stock Alerts $26.91 -0.08 (-0.30%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$26.78▼$27.2050-Day Range$26.91▼$31.5752-Week Range$19.71▼$37.10Volume1.43 million shsAverage Volume1.24 million shsMarket Capitalization$5.02 billionP/E Ratio40.77Dividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside4.1% Upside$28.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 6 Articles This WeekInsider TradingSelling Shares$141,350 Sold Last QuarterProj. Earnings Growth6.94%From $0.72 to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 starsMedical Sector603rd out of 938 stocksCustom Computer Programming Services Industry18th out of 26 stocks 2.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 9 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Doximity has a forecasted upside of 4.1% from its current price of $26.91.Amount of Analyst CoverageDoximity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 2.4 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Doximity this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows9 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $141,350.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 6.94% in the coming year, from $0.72 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 40.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 40.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 198.50.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comDoximity, Inc. (NASDAQ:DOCS) Receives Average Rating of "Hold" from AnalystsMarch 26, 2024 | msn.comAnalyst issues a warning as Reddit stock 'goes to the moon'March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | americanbankingnews.comDoximity Sees Unusually Large Options Volume (NASDAQ:DOCS)March 19, 2024 | americanbankingnews.comDoximity (NASDAQ:DOCS) Given New $25.00 Price Target at JPMorgan Chase & Co.March 18, 2024 | finance.yahoo.comDOCS Apr 2024 37.500 callMarch 15, 2024 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About DoximityMarch 13, 2024 | wsj.comDoximity Inc.March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 27, 2024 | msn.comLeerink Partners Initiates Coverage of Doximity (DOCS) with Market Perform RecommendationFebruary 26, 2024 | markets.businessinsider.comForecasting The Future: 5 Analyst Projections For DoximityFebruary 25, 2024 | ca.finance.yahoo.comDOCS Apr 2024 40.000 callFebruary 25, 2024 | msn.comDoximity (DOCS) Price Target Increased by 5.88% to 29.66February 24, 2024 | msn.comAnalysts Predict 2024 Will Be a ‘Stock Picker’s Paradise’: 4 Stocks To Buy Now To Ride Next Year’s Market UpswingFebruary 22, 2024 | businesswire.comDoximity to Participate in Upcoming Investor EventsFebruary 21, 2024 | fool.com2 Beaten-Down Stocks to Buy and Hold for 10 YearsFebruary 21, 2024 | fool.com1 Cash-Gushing Stock Down 70% to Buy and Hold ForeverFebruary 20, 2024 | seekingalpha.comDoximity: Rating Upgrade To Buy As Outlook Turns PositiveFebruary 18, 2024 | finance.yahoo.comDOCS Mar 2024 22.500 putFebruary 18, 2024 | finance.yahoo.comDOCS Mar 2024 35.000 callFebruary 15, 2024 | ca.finance.yahoo.comDOCS Feb 2024 12.500 callFebruary 11, 2024 | ca.finance.yahoo.comDOCS Aug 2024 32.500 putFebruary 11, 2024 | ca.finance.yahoo.comDOCS Mar 2024 25.000 putFebruary 10, 2024 | markets.businessinsider.comDoximity (DOCS) Maintains Hold Rating Amid Mixed Growth Signals and Potential CatalystsFebruary 9, 2024 | markets.businessinsider.comDoximity (DOCS) Hold Rating Maintained Amid Growth Potential and Market UncertaintiesFebruary 9, 2024 | markets.businessinsider.comWhat's Going With Medical Professionals-Networking Service Doximity Stock Today?February 9, 2024 | uk.investing.comDoximity's Q3 numbers beat estimates; Jefferies 'surprised at weakness' in sharesSee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today3/29/2024Fiscal Year End3/31/2024Next Earnings (Estimated)5/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$33.00 Low Stock Price Target$21.00 Potential Upside/Downside+4.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio40.77 Forward P/E Ratio37.38 P/E Growth3.62Net Income$112.82 million Net Margins29.39% Pretax Margin37.15% Return on Equity16.08% Return on Assets13.76% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$468.33 million Price / Sales10.72 Cash Flow$0.72 per share Price / Cash Flow37.57 Book Value$4.98 per share Price / Book5.40Miscellaneous Outstanding Shares186,554,000Free Float113,052,000Market Cap$5.02 billion OptionableNot Optionable Beta1.18 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsHalozyme TherapeuticsNASDAQ:HALORevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSMadrigal PharmaceuticalsNASDAQ:MDGLBridgeBio PharmaNASDAQ:BBIOView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Sold 470 shares on 3/28/2024Ownership: 0.002%PNC Financial Services Group Inc.Sold 3,114 shares on 3/22/2024Ownership: 0.002%Vanguard Group Inc.Sold 137,827 shares on 3/11/2024Ownership: 5.843%Wellington Management Group LLPBought 11,849 shares on 3/5/2024Ownership: 0.020%American International Group Inc.Sold 17,181 shares on 2/28/2024Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 13 Wall Street analysts have issued 1 year price objectives for Doximity's shares. Their DOCS share price targets range from $21.00 to $33.00. On average, they predict the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 4.1% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the start of the year. Since then, DOCS stock has decreased by 4.0% and is now trading at $26.91. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) posted its earnings results on Thursday, February, 8th. The company reported $0.25 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.06. The company earned $135.28 million during the quarter, compared to analysts' expectations of $127.46 million. Doximity had a trailing twelve-month return on equity of 16.08% and a net margin of 29.39%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Jacob Forward ETF (JFWD), Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Syntax Stratified MidCap ETF (SMDY), Natixis U.S. Equity Opportunities ETF (EQOP) and BlackRock Future Innovators ETF (BFTR). What guidance has Doximity issued on next quarter's earnings? Doximity issued an update on its FY 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $473.3 million-$474.3 million, compared to the consensus revenue estimate of $467.3 million. When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering on Thursday, June 24th 2021. The company issued 23,300,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities acted as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.86%), Vanguard Group Inc. (5.84%), Baillie Gifford & Co. (3.39%), Clearbridge Investments LLC (3.19%), Edmond DE Rothschild Holding S.A. (1.24%) and Norges Bank (0.69%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.